Adaptive Biotechnologies Corp Costs and Expenses in USD from 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Adaptive Biotechnologies Corp quarterly/annual Costs and Expenses history and growth rate from 2017 to Q3 2025.
  • Adaptive Biotechnologies Corp Costs and Expenses for the quarter ending September 30, 2025 was $83.7M, a 5.84% increase year-over-year.
  • Adaptive Biotechnologies Corp Costs and Expenses for the twelve months ending September 30, 2025 was $331M, a 12.2% decline year-over-year.
  • Adaptive Biotechnologies Corp annual Costs and Expenses for 2024 was $342M, a 14% decline from 2023.
  • Adaptive Biotechnologies Corp annual Costs and Expenses for 2023 was $397M, a 3.07% increase from 2022.
  • Adaptive Biotechnologies Corp annual Costs and Expenses for 2022 was $385M, a 6.11% increase from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Growth (%)

Adaptive Biotechnologies Corp Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $331M $83.7M +$4.62M +5.84% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $326M $83.9M -$6.59M -7.28% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $333M $82M -$8.59M -9.48% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $342M $81.3M -$35.6M -30.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $377M $79.1M -$9.81M -11% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $387M $90.5M -$6.24M -6.45% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $393M $90.6M -$4.21M -4.43% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 $397M $117M +$22.5M +23.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $375M $88.9M -$4.39M -4.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $379M $96.7M +$582K +0.61% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $379M $94.8M -$6.85M -6.73% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $385M $94.4M -$5.14M -5.17% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 $391M $93.3M -$2.53M -2.64% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $393M $96.2M +$7.89M +8.94% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $385M $102M +$22M +27.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $363M $99.5M +$25.1M +33.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $338M $95.8M +$32.4M +51.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $306M $88.3M +$30.4M +52.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $275M $79.7M +$24.2M +43.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $251M $74.4M +$26M +53.8% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-14
Q3 2020 $225M $63.3M +$19.2M +43.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $206M $57.9M +$19.7M +51.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $186M $55.5M +$22.8M +69.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $163M $48.4M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 $44.1M +$17.8M +67.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $38.2M +$13.4M +53.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $32.7M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q3 2018 $26.3M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $24.9M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13

Adaptive Biotechnologies Corp Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $342M -$55.8M -14% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $397M +$11.8M +3.07% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $385M +$22.2M +6.11% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 $363M +$112M +44.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 $251M +$87.7M +53.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-14
2019 $163M +$58M +55.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $105M +$22.5M +27.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
2017 $82.9M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.